|Summary sheet: 5-MeO-MiPT|
|Common names||5-MeO-MiPT, Moxy|
|Psychoactive class||Psychedelic / Entactogen|
|Routes of Administration|
5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT and moxy) is a lesser-known psychedelic substance of the tryptamine class. 5-MeO-MiPT is chemically related to tryptamines like 5-MeO-DMT and 5-MeO-DiPT. It produces its psychoactive effects through activity at serotonin receptors in the brain.
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin. Its effects in humans was documented in Shulgin's book TiHKAL ("Tryptamines I Have Known and Loved").
Anecdotal reports describe 5-MeO-MiPT's effects as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices when using this substance.
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT).
5-MeO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, it also shows fairly strong binding affinity to the SERT and NET, thereby acting as a moderately potent serotonin-norepinephrine reuptake inhibitor. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptamine psychedelic like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Stimulation - At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of LSD.
- Spontaneous bodily sensations - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
- Nausea - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to 5-MeO-DiPT, this substance has a much lower tendency to trigger unpleasant physical reactions.
- Bodily pressures
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Headaches
- Stomach bloating - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
- Pupil dilation
- Drifting (Melting, Breathing, Warping and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
- After images
- Symmetrical texture repetition
- Colour shifting
- Scenery slicing
The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.
- Analysis enhancement
- Empathy, affection, and sociability enhancement - This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
- Depersonalization - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
- Conceptual thinking
- Increased music appreciation
- Emotion enhancement
- Increased libido
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from ProTestKit.
|Freebase||Orange - brown||Orange red||Deep greenish brown||Unknown||Purple||No reaction||No reaction|
|HCl||Orange - brown||Red - brown||Greenish brown||Brown||Violet - purple||Green||Unknown|
Toxicity and harm potential
The toxicity and long-term health effects of recreational 5-MeO-MiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-MiPT is a research chemical with very little history of human usage.
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
5-MeO-MiPT is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-MiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- 2C-T-X - Both classes of compounds can be unpredictable alone.
- 2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
- Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
- DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
- MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
- Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
- NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
- Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- DXM - Little information exists about this combination.
- Tramadol - Increased risk of serotonin syndrome.
- aMT - Increased risk of serotonin syndrome.
- MAOIs - Increased risk of serotonin syndrome.
- PCP - Little information exists about this combination. May increase risk of psychosis and excessive stimulation.
There are no known deaths from 5-MeO-MiPT but, as a monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.
- Brazil: 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.
- China: 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.
- Finland: 5-MeO-MiPT was banned in Finland in December 2014.
- Germany: 5-MeO-MiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.
- Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
- Latvia: 5-MeO-MiPT is a Schedule I drug in Latvia.
- Luxembourg: 5-MeO-MiPT is not cited in the list of prohibited substances. Therefore, it is still a legal substance.
- New Zealand: 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.
- Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
- Switzerland: 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.
- United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
- United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Repke, D. B.; Grotjahn, D. B.; Shulgin, A. T. (1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry. 28 (7): 892–896. doi:10.1021/jm00145a007. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 4009612.
- Shulgin, Alexander; Shulgin, Ann (1997). "#40. 5-MeO-MiPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- Nagai, F.; Nonaka, R.; Satoh, K.; Kamimura, H. (2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. eISSN 1879-0712. ISSN 0014-2999. OCLC 01568459. PMID 17223101.
- Ray, T. S. (4 March 2010). "Correction: Psychedelics and the Human Receptorome". PLoS ONE. 5 (3). doi:10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4. ISSN 1932-6203.
- Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271.
- "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016.
- "Erowid China Psychoactive Law Update: September 2015" (PDF). Erowid. Retrieved September 29, 2020.
- "1130/2014: Valtioneuvoston asetus: kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" (PDF). Suomen Säädöskokoelma (in Finnish). December 19, 2014.
- "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095.
- "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie.
- "Schedule 1: Class A controlled drugs". Misuse of Drugs Act 1975. Parliamentary Counsel Office (PCO). Retrieved September 19, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.
- "The 2015 Florida Statutes - Chapter 893". The Florida Legislature. Retrieved July 18, 2020.
- "5-MeO-MIPT: Legal Status". Erowid. July 7, 2005. Retrieved September 29, 2020.
- "2019 Minnesota Statutes". Office of the Revisor of Statutes. 2019. Retrieved September 29, 2020.